...
首页> 外文期刊>Saudi Journal of OphthalmologybElectronic resource >Safety and efficacy of Ahmed glaucoma valve implantation in refractory glaucomas in Northern Indian eyes
【24h】

Safety and efficacy of Ahmed glaucoma valve implantation in refractory glaucomas in Northern Indian eyes

机译:印度北部眼难治性青光眼Ahmed青光眼瓣膜植入术的安全性和有效性

获取原文
           

摘要

Purpose To evaluate the safety and efficacy of Ahmed glaucoma valve (AGV) implantation in refractory glaucoma in Northern Indian eyes. Background The success rate of trabeculectomy remains low in cases of refractory glaucoma even with the use of antifibrotics. Glaucoma drainage devices have proven to be more efficacious in reducing intraocular pressure (IOP) in these glaucomas. Methods Retrospective records of 55 consecutive patients who underwent AGV implantation at Dr. Shroff’s Charity Eye Hospital, New Delhi, India from January 2003 to December 2012 were reviewed. Pre-operative data included age, gender, eye laterality, specific diagnosis, number of anti-glaucoma medications, number of prior incisional surgeries, visual acuity and IOP on medical treatment. Postoperative data included visual acuity and IOP on day one, 1 week, 1 month, 3 months, 6 months, 1 year and yearly thereafter, number of anti-glaucoma medications, any complication or additional surgical intervention required. Success was defined as IOP 5 and 22 mmHg with or without treatment. Results Mean IOP decreased from 39.71 ± 8.99 pre-operatively to 17.52 ± 5.72 mmHg at last follow-up ( p 0.001) and number of medications reduced from 3.27 ± 0.84 to 1.25 ± 0.88 ( p 0.001). Visual acuity remained within one Snellen line or improved at last follow-up in 47 cases (85.4%). The cumulative probability of success was 85.45% at 1 year and 79.63% at 3 years. The incidence of post-operative complications was 25.45%. Conclusion AGV implantation has proven to be safe and is effective in controlling IOP in refractory glaucoma in Northern Indian eyes.
机译:目的评估印度北部眼难治性青光眼中艾哈迈德青光眼瓣膜(AGV)植入的安全性和有效性。背景技术即使使用抗纤维药物,难治性青光眼小梁切除术的成功率仍然很低。青光眼引流装置已被证明在降低这些青光眼的眼内压(IOP)方面更有效。方法回顾性分析了2003年1月至2012年12月在印度新德里Shroff博士慈善眼科医院接受AGV植入的55例连续患者的回顾性记录。术前数据包括年龄,性别,眼球偏斜度,具体诊断,抗青光眼药物治疗的数量,先前的切开手术次数,视力和药物治疗的眼压。术后数据包括术后1天,1周,1个月,3个月,6个月,1年和每年的视力和眼压,抗青光眼药物的使用数量,任何并发症或需要进行的其他外科手术干预。成功定义为接受或不接受治疗的IOP> 5和<22 mmHg。结果平均眼压从术前的39.71±8.99降至最后一次随访时的17.52±5.72 mmHg(p <0.001),药物数量从3.27±0.84降低至1.25±0.88(p <0.001)。 47例(85.4%)的视力仍在一个Snellen线以内或在最后一次随访时有所改善。累积成功的概率在1年时为85.45%,在3年时为79.63%。术后并发症发生率为25.45%。结论AGV植入已被证明是安全的,可有效控制印度北部难治性青光眼的眼压。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号